Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
SueWallSt (powered by Levi & Korsinsky) announced an investigation into whether Xenon Pharmaceuticals made misleading statements about azetukalner's safety profile in its psychiatry program. The release recaps prior news: a Phase 3 enrollment pause after neuropsychiatric adverse events, a 30.7% share decline, Needham stripping MDD/bipolar sales projections, and a Deutsche Bank downgrade to Hold.
Key figures
- Planned patients
- 450
- Stock decline pct
- 30.7%
- Patients unblinding
- 360
- After hours decline pct
- 22%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.